Loading
A phase 1/2 trial of AZD0754 in prostate cancer, run by AstraZeneca, now recruiting.
Study of AZD0754 in Participants With Metastatic Prostate Cancer is a phase 1/2 interventional study registered as NCT06267729 by AstraZeneca, with 60 participants planned, started 2024-03-12 and due to reach its primary completion in 2026-11-24. Interventions recorded: AZD0754 and AZD2287.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares AstraZeneca, Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares Prostate cancer and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Shares AstraZeneca and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/